a Zanjan Pharmaceutical Nanotechnology Research Center, Zanjan University of Medical Sciences , Zanjan , Iran.
b Department of Pharmaceutical Nanotechnology , School of Pharmacy, Zanjan University of Medical Sciences , Zanjan , Iran.
Artif Cells Nanomed Biotechnol. 2018 Dec;46(8):1625-1636. doi: 10.1080/21691401.2017.1386191. Epub 2017 Nov 3.
In this study, drug delivery system of gliclazide, a poorly soluble drug, was developed and evaluated in vitro and in vivo. We synthesized five series of mPEG-PCL di block copolymers. The structure of the copolymers was characterized by H-NMR, Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC) and gel permeation chromatography (GPC) techniques. In this study, gliclazide was encapsulated within micelles through a single-step nano-precipitation method, leading to formation of gliclazide/mPEG-PCL micelles. The resulting micelles were characterized further by various techniques such as DLS and AFM. The serum glucose lowering effect of gliclazide micelles was studied in streptozotocin-diabetic rats and were compared with the gliclazide treated rats. The results showed that the zeta potential of micelles was about -14.9 mV and the average size was 83.12 nm. Gliclazide was encapsulated into mPEG-PCL micelles with loading capacity of 21.05 ± 0.14% and entrapment efficiency of 94.11 ± 0.12%. In vivo testing of the gliclazide micelles in diabetic rats demonstrated a significant antidiabetic effect of gliclazide micelles after the 7 day that lasted for 21 days when compared with gliclazide powder. The results suggest that gliclazide micelles are a valuable system for the sustained delivery of gliclazide.
在这项研究中,我们开发并评估了一种难溶性药物格列齐特的药物传递系统。我们合成了五组 mPEG-PCL 二嵌段共聚物。通过 1H-NMR、傅里叶变换红外光谱(FT-IR)、差示扫描量热法(DSC)和凝胶渗透色谱(GPC)技术对共聚物的结构进行了表征。在这项研究中,格列齐特通过单步纳米沉淀法包封在胶束中,形成格列齐特/mPEG-PCL 胶束。通过 DLS 和 AFM 等各种技术进一步对所得胶束进行了表征。在链脲佐菌素诱导的糖尿病大鼠中研究了格列齐特胶束的降血糖作用,并与格列齐特处理的大鼠进行了比较。结果表明,胶束的zeta 电位约为-14.9 mV,平均粒径为 83.12nm。格列齐特以 21.05±0.14%的载药量和 94.11±0.12%的包封效率被包封到 mPEG-PCL 胶束中。在糖尿病大鼠体内试验中,与格列齐特粉末相比,格列齐特胶束在第 7 天开始具有显著的降血糖作用,并持续了 21 天。结果表明,格列齐特胶束是一种有价值的格列齐特持续释放系统。